Eledon Pharmaceuticals to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022

Rhea-AI Summary

Eledon Pharmaceuticals (NASDAQ: ELDN) will release its Q1 2022 financial results on May 12, 2022, following market close. A conference call and webcast are scheduled for 4:30 p.m. ET to discuss these results. Eledon focuses on developing treatments for organ and cell transplantation, autoimmune diseases, and neurodegenerative conditions. Their lead candidate, tegoprubart, targets the CD40 Ligand pathway and shows potential across various therapeutic areas. After the live event, the webcast will be archived on Eledon's website.

Positive

• Scheduled release of Q1 2022 results may indicate improved financial transparency.
• Focus on a robust clinical pipeline with tegoprubart as a promising lead compound.

Negative

• None.

Management to host conference call and webcast at 4:30 p.m. ET

IRVINE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease, today announced that it plans to release financial results for the first quarter ended March 31, 2022 on Thursday, May 12, after the close of trading. Eledon’s management team will host a conference call and webcast beginning at 4:30 p.m. ET.

Conference Call and Webcast Details:

Thursday, May 12, 2022 at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time
Toll Free: 877-407-9039 
International: 201-689-8470 
Conference ID: 13729260
Webcast: https://ir.eledon.com/events-and-presentations/events

After the live webcast, the event will be archived on Eledon’s website for one year.

About Eledon Pharmaceuticals and tegoprubart (formerly AT-1501)

Eledon Pharmaceuticals is a clinical stage biotechnology company using its expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop potential treatments for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with ALS. The company’s lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target with broad therapeutic potential. Eledon is headquartered in Irvine, Calif. For more information, please visit the company’s website at www.eledon.com.

Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter

Investor Contact:

Stephen Jasper
Gilmartin Group
(858) 525 2047
stephen@gilmartinir.com

FAQ

When will Eledon Pharmaceuticals announce its Q1 2022 financial results?

Eledon Pharmaceuticals will announce its Q1 2022 financial results on May 12, 2022.

What time is the Eledon Pharmaceuticals conference call on May 12, 2022?

The conference call will take place at 4:30 p.m. ET on May 12, 2022.

What is the focus of Eledon Pharmaceuticals?

Eledon Pharmaceuticals focuses on developing treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative diseases.

What is the lead compound of Eledon Pharmaceuticals?

Eledon's lead compound is tegoprubart, which targets the CD40 Ligand pathway.

Where can I find the archived webcast of Eledon's financial results call?

The archived webcast will be available on Eledon's website after the live event.